Options for early breast cancer follow-up in primary and secondary care - a systematic review

BMC Cancer

Research Article

Peter Donnelly¹  Frances Taggart²  Janet Dunn² 

[1] Breast Care Directorate, South Devon Healthcare NHS Foundation Trust, TQ2 7AA, Lawes Bridge, Torquay, UK;Warwick Medical School Clinical Trials Unit, University of Warwick, CV4 7AL, Coventry, UK;

关键词: Breast Cancer;    Tamoxifen;    Local Recurrence;    Breast Cancer Survivor;    Aromatase Inhibitor;   

DOI  :  10.1186/1471-2407-12-238

 received in 2011-11-21, accepted in 2012-06-13,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundBoth incidence of breast cancer and survival have increased in recent years and there is a need to review follow up strategies. This study aims to assess the evidence for benefits of follow-up in different settings for women who have had treatment for early breast cancer.MethodA systematic review to identify key criteria for follow up and then address research questions. Key criteria were: 1) Risk of second breast cancer over time - incidence compared to general population. 2) Incidence and method of detection of local recurrence and second ipsi and contra-lateral breast cancer. 3) Level 1–4 evidence of the benefits of hospital or alternative setting follow-up for survival and well-being. Data sources to identify criteria were MEDLINE, EMBASE, AMED, CINAHL, PSYCHINFO, ZETOC, Health Management Information Consortium, Science Direct. For the systematic review to address research questions searches were performed using MEDLINE (2011). Studies included were population studies using cancer registry data for incidence of new cancers, cohort studies with long term follow up for recurrence and detection of new primaries and RCTs not restricted to special populations for trials of alternative follow up and lifestyle interventions.ResultsWomen who have had breast cancer have an increased risk of a second primary breast cancer for at least 20 years compared to the general population. Mammographically detected local recurrences or those detected by women themselves gave better survival than those detected by clinical examination. Follow up in alternative settings to the specialist clinic is acceptable to women but trials are underpowered for survival.ConclusionsLong term support, surveillance mammography and fast access to medical treatment at point of need may be better than hospital based surveillance limited to five years but further large, randomised controlled trials are needed.

【 授权许可】

CC BY   
© Taggart et al.; licensee BioMed Central Ltd. 2012